Comparative Pharmacology
Head-to-head clinical analysis: CEFADROXIL versus SPECTRACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFADROXIL versus SPECTRACEF.
CEFADROXIL vs SPECTRACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefadroxil is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking.
Cefditoren, a third-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1-2 g orally once daily or divided into two doses every 12 hours.
400 mg orally twice daily for 10-14 days.
None Documented
None Documented
Terminal elimination half-life 1.1-1.5 hours in normal renal function; prolonged to 20-30 hours in end-stage renal disease (CrCl <10 mL/min).
Clinical Note
moderateCefadroxil + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefadroxil."
Clinical Note
moderateCefadroxil + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefadroxil."
Clinical Note
moderateWarfarin + Cefadroxil
"Warfarin may increase the anticoagulant activities of Cefadroxil."
Clinical Note
moderatePhenprocoumon + Cefadroxil
Terminal elimination half-life: 2.5 hours (range 2.0-3.0 hours) in healthy adults; prolonged in renal impairment (up to 10 hours in severe impairment)
Primarily renal (90-95% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal (<5%).
Renal: 88% as unchanged drug, Fecal: negligible, Biliary: minimal
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefadroxil."